AB Sciex to accelerate use of dried blood spot analysis
Offers cost savings and higher productivity
AB Sciex, a US supplier of analytical technologies for the life sciences based in Foster City, California, is to collaborate with Alturas Analytics to accelerate the adoption of dried blood spot (DBS) analysis for drug discovery and development.
DBS analysis is said to simplify the collection, storage and shipment of samples for pre-clinical and clinical studies in the drug development process.
Alturas Analytics provides LC/MS contract research services for the pharmaceutical and biotech industries.
Scientists at Alturas are using AB Sciex’s QTRAP 5500 technology and novel micro-flow chromatography technology from Eksigent, a division of AB Sciex, to develop new workflows based on microflow LC/MS (liquid chromatography/mass spectrometry) for dried blood spot analysis. These workflows require smaller sample volumes and provide sensitivity and low coefficient of variations.
According to AB Sciex, dried blood spot analysis also requires fewer animals during preclinical trials and less blood drawn during clinical trials than traditional bioanalysis.
The QTRAP 5500 System merges high sensitivity and speed on a platform that integrates quantitative and qualitative analysis. The Eksigent system provides high pressure micro-flow LC/MS and ease of operation.
Alturas scientists are developing new workflows that use MRM3 capabilities – uniquely available on the QTRAP system – eliminate the interference traditionally associated with dried matrix spot analysis, help expand the limits of quantitation and improve selectivity to a level required by drug discovery scientists.
